What’s new and what’s next for vaccines in 2026?
As the vaccines field continues to evolve, new technologies, targets, and delivery strategies are reshaping both research priorities and implementation pathways. We asked members of the Vaccine Insights Editorial Advisory Board to reflect on the areas shaping their current work and the developments they believe will influence the field in the years ahead. "Based on current trends, I expect increased focus on vaccine formulations that incorporate multiple antigens or immunogens, potentially addressing several diseases or stages within a single product." - Rajender Jena, Head Malaria Vaccines (Quality Control), Serum Institute of India Pvt Ltd, India
Authors
- Trina Racine (ORCID: https://orcid.org/0000-0001-6370-8661)
- Pierre A. Morgon
- Christopher Ton
- Cleo Kontoravdi (ORCID: https://orcid.org/0000-0003-0213-4830)
- Tim Wong
- Isis Kanevsky
- Jeffrey Ulmer
- Rajender Jena
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Pfizer (United States) (US)
- Serum Institute of India (India) (IN)
- Serimmune (United States) (US)
- Healthcentric Advisors (US)
- Institut de Recherche Vaccinale (FR)
- Imperial College London (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- Vaccine Insights
- Published
- 2026-01-29
- DOI
- https://doi.org/10.18609/vac.2026.003
- Primary Topic
- Immune responses and vaccinations
- Type
- article
- Field-Weighted Citation Impact
- 0.00